Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma

被引:0
作者
Shohet, JM
Hicks, MJ
Plon, SE
Burlingame, SM
Stuart, S
Chen, SY
Brenner, MK
Nuchtern, JG
机构
[1] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[4] Baylor Coll Med, DeBakey Dept Surg, Houston, TX 77030 USA
[5] Ctr Cell & Gene Therapy, Houston, TX 77030 USA
[6] Texas Childrens Hosp, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[7] Incyte Genom, Palo Alto, CA 94304 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The MYCN oncogene is amplified in similar to25% of neuroblastoma tumors and is the most significant negative prognostic factor. The direct transcriptional targets of MYCN in MYCN-amplified tumors have not been defined. Microarray analysis of RNA from neuroblastoma primary cell cultures revealed 10-fold higher MCM7 expression in MYCN-amplified versus nonamplified tumors. MCM7 is an essential component of DNA replication licensing factor, a hexameric protein complex that regulates DNA synthesis during the cell cycle, preventing rereplication and ensuring maintenance of DNA euploidy. Additional experiments demonstrated markedly increased expression of MCM7 RNA and protein in MYCN-amplified neuroblastoma tumors and cell tines. Induction of MYCN in conditional cell lines results in increased expression of endogenous MCM7 mRNA and a 3-fold increase in protein levels. In addition, luciferase activity from MCM7 promoter/luciferase gene reporter constructs was significantly increased under MYCN-induced conditions. Specific electrophoretic mobility shifts of MCM7 promoter sequences are detected in extracts of MYCN-amplified cells. These findings demonstrate that in neuroblastoma, the MYCN oncogene directly activates genes required for DNA replication, and this may contribute to neoplastic transformation of these MYCN-amplified tumors.
引用
收藏
页码:1123 / 1128
页数:6
相关论文
共 37 条
[1]   N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis [J].
Boon, K ;
Caron, HN ;
van Asperen, R ;
Valentijn, L ;
Hermus, MC ;
van Sluis, P ;
Roobeek, I ;
Weis, I ;
Voûte, PA ;
Schwab, M ;
Versteeg, R .
EMBO JOURNAL, 2001, 20 (06) :1383-1393
[2]   Prognostic significance of MYCN oncogene expression in childhood neuroblastoma [J].
Bordow, SB ;
Norris, MD ;
Haber, PS ;
Marshall, GM ;
Haber, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3286-3294
[3]  
Chambéry D, 1999, CANCER RES, V59, P2898
[4]  
Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO
[5]  
2-4
[6]   Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies [J].
Cook, JL ;
Zhang, Z ;
Alam, J ;
Re, RN .
ONCOGENE, 1999, 18 (14) :2373-2379
[7]   Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells [J].
Fotsis, T ;
Breit, S ;
Lutz, W ;
Rössler, J ;
Hatzi, E ;
Schwab, M ;
Schweigerer, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 263 (03) :757-764
[8]   Verification of differential gene transcription using virtual northern blotting [J].
Franz, O ;
Bruchhaus, I ;
Roeder, T .
NUCLEIC ACIDS RESEARCH, 1999, 27 (11)
[9]  
Freeman A, 1999, CLIN CANCER RES, V5, P2121
[10]   Specific distribution patterns of hCDC47 expression in cutaneous diseases [J].
Hiraiwa, A ;
Fujita, M ;
Adachi, A ;
Ono, H ;
Nagasaka, T ;
Matsumoto, Y ;
Ohashi, M ;
Tomita, Y ;
Ishibashi, M .
JOURNAL OF CUTANEOUS PATHOLOGY, 1998, 25 (06) :285-290